Glucocorticoid-induced insulin resistance is a clinically relevant paradigm that recapitulates hyperglycemia, dyslipidemia and changes in glucose transporters, including GLUT-4, under conditions of increased steroid exposur—a scenario observed in patients on chronic glucocorticoid therapy. This evidence concerns the gene SLC2A4 and metabolic syndrome.